৳ 0.00
Your Complete HealthCare Solution - Right Here
10657
info@shukhee.com
Telecom Bhaban (Level- 12), 53/1 Box Nagar, Zoo Road, Dhaka-1216.
৳ 0.00
10657
info@shukhee.com
Telecom Bhaban (Level- 12), 53/1 Box Nagar, Zoo Road, Dhaka-1216.


Quantity:
Products
Payment
Delivery
Sarozar Tablet is indicated for the treatment of diabetic dyslipidaemia and hypertriglyceridaemia in patients with Type 2 Diabetes Mellitus who are not adequately controlled with statin therapy.
Clinical studies have demonstrated that Sarozar Tablet:
Saroglitazar is a potent and predominantly Peroxisome Proliferator-Activated Receptor (PPAR)-α agonist with moderate PPAR-γ agonistic activity.
PPARs are nuclear lipid-activated transcription factors that regulate the expression of genes involved in:
Saroglitazar exhibits both antidyslipidaemic and antidiabetic effects through activation of PPAR-α and PPAR-γ receptors, respectively.
Recommended Dose:
In vitro studies indicate that Saroglitazar does not significantly inhibit CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 enzymes. It also does not induce CYP3A4 activity at clinically relevant concentrations.
Based on available data, Sarozar is unlikely to cause clinically significant drug-drug interactions associated with these CYP enzymes.
The most commonly reported adverse events (>2%) in Phase III clinical studies were:
Most adverse events were mild to moderate in severity and did not require discontinuation of therapy.
Pregnancy Category: C
The safety of Saroglitazar during pregnancy has not been established. Adequate and well-controlled studies in pregnant women are lacking.
Saroglitazar should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
It is unknown whether Saroglitazar is excreted in human breast milk. Therefore, its use is not recommended in nursing mothers.
Sarozar should be used with caution in patients with:
Patients should be monitored for:
No cases of overdose have been reported during clinical studies.
In the event of overdose:
Antidiabetic and Antidyslipidaemic Agent (PPAR-α/PPAR-γ Agonist).






Saroglitazar is an oral medication used primarily for the treatment of diabetic dyslipidemia and hypertriglyceridemia. It works as a dual PPAR (peroxisome proliferator-activated receptor) alpha and gamma agonist, helping regulate lipid and glucose metabolism.
Saroglitazar helps reduce triglycerides, improve HDL (good cholesterol), and control blood sugar levels. It is especially useful in patients with type 2 diabetes who have abnormal lipid profiles.
